Search

Your search keyword '"Pascal Dao"' showing total 5 results
Start Over Author "Pascal Dao" Topic cell line, tumor
5 results on '"Pascal Dao"'

1. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity

Author

Mélanie Etheve-Quelquejeu, Daniel Lietha, Pascal Dao, Huixiong Chen, and Christiane Garbay

Subjects
0301 basic medicine, Clinical Biochemistry, Pharmaceutical Science, Antineoplastic Agents, Biochemistry, Focal adhesion, Structure-Activity Relationship, 03 medical and health sciences, 0302 clinical medicine, Cell Line, Tumor, Neoplasms, Drug Discovery, Humans, Structure–activity relationship, Protein Kinase Inhibitors, Molecular Biology, IC50, Cell Proliferation, chemistry.chemical_classification, biology, Triazines, Kinase, Chemistry, Cell growth, Organic Chemistry, Active site, Molecular Docking Simulation, 030104 developmental biology, Enzyme, Docking (molecular), Drug Design, Focal Adhesion Protein-Tyrosine Kinases, 030220 oncology & carcinogenesis, biology.protein, Molecular Medicine, Drug Screening Assays, Antitumor
Abstract

A series of 1,3,5-triazinic inhibitors of focal adhesion kinase (FAK) has recently been shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines. In this report, we designed and synthesized a series of new compounds containing a 1,2,4-triazine core as novel scaffold for FAK inhibitors. These compounds displayed 10-7M IC50 values, and the best one showed IC50 value of 0.23μM against FAK enzymatic activity. Among them, several inhibitors potently inhibited the proliferation of glioblastoma (U-87MG) and colon (HCT-116) cancer cell lines. Docking of compound 10 into the active site of the FAK kinase was performed to explore its potential binding mode.

Published
2017

2. GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism

Author

Laura Mondragón, Philippe Gaulard, Jaap G Neels, Camila Rubio-Patiño, Frédéric Coutant, Laurent Boyer, François Lemonnier, Florian Muller, Elodie Villa, Rana Mhaidly, Vahid Asnafi, Thierry Passeron, Gian Marco De Donatis, Jean-François Peyron, Nicole Fabien, Els Verhoeyen, Sandrine Marchetti, Pascal Dao, Laura Sormani, Marie Jacquin, Marie Tosolini, Jean-Ehrland Ricci, Emma Proïcs, Anne Doye, Laurent Genestier, Jozef P. Bossowski, Anthony Martin, Véronique Imbert, Frederic Luciano, Jean-Jacques Fournié, Rachid Benhida, Caroline Pons, Johanna Chiche, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie de Nice (ICN), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Hospices Civils de Lyon (HCL), Centre méditérannéen de médecine moléculaire (C3M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie de la survie et de la mort cellulaire et infection virale, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Université Nice Sophia Antipolis (... - 2019) (UNS), Université Nice Sophia Antipolis (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Service d'immunologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Immunogenomique et Inflammation, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Centre de Recherche en Cancérologie de Toulouse (CRCT), Virus enveloppés, vecteurs et immunothérapie – Enveloped viruses, Vectors and Immuno-therapy (Equipe EVIR), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université Côte d'Azur (UCA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR50-Université Nice Sophia Antipolis (... - 2019) (UNS), and Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)

Subjects
0301 basic medicine, Male, Cancer Research, [SDV]Life Sciences [q-bio], T-Lymphocytes, Datasets as Topic, chemistry.chemical_compound, 0302 clinical medicine, Glyceraldehyde 3-phosphate dehydrogenase, ComputingMilieux_MISCELLANEOUS, biology, NF-kappa B, Middle Aged, 3. Good health, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Gene Knockdown Techniques, Female, Signal Transduction, Genetically modified mouse, Angioimmunoblastic T-cell lymphoma, Lineage (genetic), T cell, [SDV.CAN]Life Sciences [q-bio]/Cancer, Mice, Transgenic, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Protein Serine-Threonine Kinases, Lymphoma, T-Cell, 03 medical and health sciences, stomatognathic system, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cell Line, Tumor, medicine, Animals, Humans, Cell Lineage, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, Protein Kinase Inhibitors, Aged, NF-κB, medicine.disease, Lymphoma, Disease Models, Animal, 030104 developmental biology, HEK293 Cells, chemistry, Immunoblastic Lymphadenopathy, biology.protein, Cancer research, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating), Function (biology)
Abstract

GAPDH is emerging as a key player in T cell development and function. To investigate the role of GAPDH in T cells, we generated a transgenic mouse model overexpressing GAPDH in the T cell lineage. Aged mice developed a peripheral Tfh-like lymphoma that recapitulated key molecular, pathological, and immunophenotypic features of human angioimmunoblastic T cell lymphoma (AITL). GAPDH induced non-canonical NF-κB pathway activation in mouse T cells, which was strongly activated in human AITL. We developed a NIK inhibitor to reveal that targeting the NF-κB pathway prolonged AITL-bearing mouse survival alone and in combination with anti-PD-1. These findings suggest the therapeutic potential of targeting NF-κB signaling in AITL and provide a model for future AITL therapeutic investigations.

Published
2018

3. Development of highly sensitive fluorescent probes for the detection of β-galactosidase activity – application to the real-time monitoring of senescence in live cells

Author

Pascal Dao, Anthony Martin, Mauro Safir Filho, Maeva Gesson, Rachid Benhida, Institut de Chimie de Nice (ICN), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Fundação) = CAPES Foundation [Brasilia] (CAPES), Centre méditerranéen de médecine moléculaire (C3M), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)

Subjects
Confocal, 02 engineering and technology, 010402 general chemistry, 01 natural sciences, Biochemistry, Analytical Chemistry, Flow cytometry, Cell Line, Tumor, Electrochemistry, medicine, Fluorescence microscope, Environmental Chemistry, Humans, [CHIM]Chemical Sciences, Spectroscopy, Cellular Senescence, Fluorescent Dyes, medicine.diagnostic_test, Chemistry, Galactosidase activity, 021001 nanoscience & nanotechnology, Flow Cytometry, beta-Galactosidase, Fluorescence, In vitro, 0104 chemical sciences, Microscopy, Fluorescence, Cell culture, Biophysics, 0210 nano-technology, Linker, Biomarkers
Abstract

International audience; We report the development of four novel fluorescent probes to monitor the activity of the β-galactosidase enzyme (β-gal), in vitro and in living cells. The fluorophores are based on a 6-amino-styryl-benzothiazole push-pull core and display a strong ICT emission. The probes encompass the fluorescent motif that is connected to a β-D-galactopyranoside moiety through a self-immolative benzyl carbamate linker (βGal-1-4). The screening of four different fluorophores enabled us to access new light-up and two-band ratiometric reporters. The four probes, βGal-1-4, exhibited an extremely fast response and over 200-fold fluorescence enhancement (βGal-1) following the enzymatic cleavage of the β-D-galactopyranoside unit. This rapid and extremely sensitive response allowed the detection of senescence-associated β-galactosidase (SA-β-gal) activity; a widely used biomarker of senescence. More importantly, βGal-1 also enabled us to monitor, in real-time, the emergence of senescence in live cells, i.e. the phenotypic transformation from normal to senescent cell. These findings underpin the fact that βGal-1 may find useful applications in biomedical research. Importantly, βGal-1 is suitable for epifluorescence and confocal microscopies, and flow cytometry techniques; which are among the most common analytical tools in biology.

Published
2018

4. Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity

Author

Xavier Coumoul, Jean-Phillipe Herbeuval, Céline Tomkiewicz-Raulet, Christiane Garbay, Nikaïa Smith, Marta Camacho-Artacho, Huixiong Chen, Pascal Dao, Daniel Lietha, and Expédite Yen-Pon

Subjects
Models, Molecular, Cell Survival, Antineoplastic Agents, Apoptosis, Focal adhesion, Cell Movement, Cell Line, Tumor, Drug Discovery, Cell Adhesion, Humans, Phosphorylation, Protein Kinase Inhibitors, IC50, chemistry.chemical_classification, Dose-Response Relationship, Drug, Molecular Structure, Triazines, Chemistry, Cell growth, Imidazoles, Adhesion, Cell cycle, HCT116 Cells, Protein Structure, Tertiary, G2 Phase Cell Cycle Checkpoints, Enzyme, Models, Chemical, Biochemistry, Cell culture, Drug Design, Focal Adhesion Protein-Tyrosine Kinases, Molecular Medicine, Protein Binding
Abstract

A series of triazinic inhibitors of focal adhesion kinase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines. We report herein that we further explored the heterocyclic core of these inhibitors by a fused imidazole ring with the triazine to provide imidazo[1,2-a][1,3,5]triazines. Importantly, these new compounds displayed 10(-7)-10(-8) M IC50 values, and the best inhibitor showed IC50 value of 50 nM against FAK enzymatic activity. Several inhibitors potently inhibited the proliferation of a panel of cancer cell lines expressing high levels of FAK. Apoptosis analysis in U87-MG and HCT-116 cell lines suggested that these compounds delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth. Further investigation demonstrated that these compounds strongly inhibited cell-matrix adhesion, migration, and invasion of U87-MG cells.

Published
2014

5. Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11

Author

Pascal Dao, Nikaïa Smith, Daniel Scott-Algara, Christiane Garbay, Huixiong Chen, Jean-Philippe Herbeuval, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Régulation des Infections Rétrovirales, Institut Pasteur [Paris], and Institut Pasteur [Paris] (IP)

Subjects
MESH: Signal Transduction, Cancer Research, MESH: CASP8 and FADD-Like Apoptosis Regulating Protein, Time Factors, MESH: Triazines, CASP8 and FADD-Like Apoptosis Regulating Protein, Apoptosis, TRAIL, FAK inhibitor, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, MESH: Dose-Response Relationship, Drug, TNF-Related Apoptosis-Inducing Ligand, 0302 clinical medicine, MESH: Molecular Targeted Therapy, Medicine, MESH: Protein Kinase Inhibitors, Molecular Targeted Therapy, 0303 health sciences, Kinase, Triazines, Imidazoles, MESH: Drug Resistance, Neoplasm, 3. Good health, Cell biology, Oncology, 030220 oncology & carcinogenesis, Caspases, [SDV.IMM]Life Sciences [q-bio]/Immunology, Tumor necrosis factor alpha, RNA Interference, MESH: Pancreatic Neoplasms, MESH: TNF-Related Apoptosis-Inducing Ligand, MESH: Imidazoles, Signal Transduction, MESH: Focal Adhesion Kinase 1, MESH: Enzyme Activation, c-FLIP, MESH: Cell Line, Tumor, MESH: RNA Interference, Antineoplastic Agents, Transfection, Focal adhesion, 03 medical and health sciences, Pancreatic cancer, Cell Line, Tumor, Humans, Protein kinase B, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, 030304 developmental biology, Pancreatic cancer cell lines, MESH: Caspases, MESH: Humans, Dose-Response Relationship, Drug, business.industry, MESH: Proto-Oncogene Proteins c-akt, MESH: Apoptosis, MESH: Transfection, MESH: Time Factors, Cancer, medicine.disease, Enzyme Activation, Pancreatic Neoplasms, PI3K/AKT pathway, Drug Resistance, Neoplasm, Focal Adhesion Kinase 1, Cancer research, MESH: Antineoplastic Agents, MESH: Phosphatidylinositol 3-Kinase, Phosphatidylinositol 3-Kinase, business, Proto-Oncogene Proteins c-akt
Abstract

International audience; Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) emerges as one of the most-promising experimental cancer therapeutic drugs and is currently being tested in clinical trials. However, both intrinsic and acquired resistance of human cancer cells to TRAIL-induced apoptosis poses a huge problem in establishing clinically efficient TRAIL therapies. To assess the regulation of TRAIL-resistance in human pancreatic cancer cells, we studied the TRAIL resistant pancreatic cell line PANC-1. We show that treatment with PH11, a novel Focal Adhesion Kinase (FAK) inhibitor in association with TRAIL rapidly induces apoptosis in TRAIL-resistant PANC-1 cells, but not in normal human fibroblast cells. To explain sensitization, we showed that PH11 restores TRAIL apoptotic pathway in PANC-1 cells through down-regulation of c-FLIP via inhibition of FAK and the phosphatidylinositol-3 kinase (PI3K)/AKT pathways. These findings suggest that this combined treatment may offer an attractive therapeutic strategy for safely and efficiently treating pancreatic cancer.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results